News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
857,066 Results
Type
Article (77553)
Company Profile (348)
Press Release (779140)
Multimedia
Podcasts (283)
Webinars (43)
Section
Business (258798)
Career Advice (3849)
Deals (38893)
Drug Delivery (245)
Drug Development (88981)
Employer Resources (212)
FDA (18530)
Job Trends (17117)
News (385926)
Policy (38619)
Tag
2025 Best Places to Work (21)
2026 Best Places to Work (33)
2027 BioCapital Standard (5)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (9)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (6)
2027 Genetown Elite (3)
2027 Genetown Standard (6)
2027 Pharm Country Digital (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
40 Under 40 (4)
Academia (3111)
Academic (2)
Accelerated approval (76)
ADA (54)
Adcomms (44)
Allergies (236)
Alliances (55807)
ALS (289)
Alzheimer's disease (2136)
Antibody-drug conjugate (ADC) (771)
Approvals (19117)
Artificial intelligence (1086)
ASCO (349)
Autoimmune disease (529)
Automation (84)
Bankruptcy (394)
Belgium (43)
Best Places to Work (12624)
BIO (83)
Biologics (115)
BIOSECURE Act (23)
Biosimilars (306)
BioSpace Insights (269)
Biotechnology (240)
Bispecific (58)
Bladder cancer (249)
Brain cancer (101)
Breast cancer (970)
Cancer (7988)
Cardiovascular disease (679)
Career advice (3338)
Career pathing (65)
CAR-T (461)
CDC (82)
CDMO (234)
Celiac Disease (7)
Cell-line development (2)
Cell therapy (1248)
Cervical cancer (67)
Clinical research (78667)
Collaboration (2875)
Commercialization (75)
Company closure (10)
Compensation (1931)
Complete response letters (127)
COVID-19 (3085)
CRISPR (154)
CRO (7)
C-suite (1708)
Cystic fibrosis (182)
Data (11108)
Decentralized trials (4)
Denatured (112)
Depression (227)
Dermatology (207)
Diabetes (842)
Diagnostics (7931)
Digital health (83)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (531)
Drug pricing (253)
Drug shortages (41)
Duchenne muscular dystrophy (388)
Earnings (100520)
Editorial (85)
Employer branding (27)
Employer resources (184)
ESMO (437)
Events (138042)
Executive appointments (1381)
Eye disease (25)
FDA (23603)
Fibrodysplasia Ossificans Progressiva (17)
Fragile X (6)
Friedreich's ataxia (29)
Frontotemporal dementia (42)
Funding (2356)
Gene editing (322)
Generative AI (103)
Gene therapy (979)
GLP-1 (1408)
Government (5590)
Grass and pollen (8)
Guidances (446)
Healthcare (21483)
Hematology (233)
HIV (125)
Huntington's disease (93)
Idiopathic pulmonary fibrosis (15)
IgA nephropathy (155)
Immunology and inflammation (429)
Immuno-oncology (166)
Indications (296)
Infectious disease (3543)
Inflammatory bowel disease (284)
Inflation Reduction Act (17)
Influenza (166)
Intellectual property (384)
Interviews (753)
IPO (17818)
IRA (61)
Job creations (4768)
Job search strategy (2661)
JPM (73)
Kidney cancer (30)
Kidney disease (179)
Labor market (152)
Layoffs (731)
Leadership (70)
Legal (9651)
Licensing (124)
Liver cancer (121)
Longevity (57)
Lung cancer (1102)
Lung diease (27)
Lymphoma (564)
Machine learning (77)
Management (72)
Manufacturing (1635)
Marketing (39)
MASH (260)
Medical affairs (5)
Medical device (15436)
Medtech (15772)
Mergers & acquisitions (22639)
Metabolic disorders (2143)
Middle East (2)
mRNA (344)
Multiple sclerosis (261)
Multispecific (6)
NASH (24)
Netherlands (39)
Neurodegenerative disease (632)
Neuropsychiatric disorders (154)
Neuroscience (4333)
Neurotech (3)
NextGen: Class of 2026 (7595)
Non-profit (5175)
Now hiring (100)
Obesity (1012)
Opinion (409)
Ovarian cancer (299)
Pain (349)
Pancreatic cancer (454)
Parkinson's disease (492)
Partnered (50)
Patents (804)
Patient advocacy (8)
Patient recruitment (988)
Patient selection (117)
Peanut (81)
People (67604)
Peptides (42)
Pharmaceutical (68)
Pharmacy benefit managers (43)
Phase 1 (24374)
Phase 2 (34276)
Phase 3 (25965)
Pipeline (14545)
Policy (434)
Postmarket research (3156)
Preclinical (10660)
Press Release (74)
Prostate cancer (410)
Psychedelics (102)
Radioligand (3)
Radiopharmaceuticals (447)
Rare diseases (1611)
Real estate (7112)
Recruiting (84)
Regenerative medicine (37)
Regulatory (31017)
Reports (102)
Research institute (2814)
Resumes & cover letters (611)
Rett syndrome (59)
RNA editing (39)
RSV (106)
Saudi Arabia (1)
Schizophrenia (229)
Series A (409)
Series B (284)
Service/supplier (15)
Sickle cell disease (151)
Special edition (38)
Spinal muscular atrophy (199)
Sponsored (61)
Startups (4214)
State (2)
Stem cells (8)
Stomach cancer (24)
Substance use disorders (23)
Supply chain (171)
Switzerland (20)
Tariffs (108)
Tax incentives (2)
The Weekly (168)
Vaccines (1442)
Venture capital (184)
Weight loss (673)
Wet AMD (7)
Women's health (190)
Women in leadership (1)
Worklife (28)
Date
Today (1)
Last 7 days (955)
Last 30 days (3663)
Last 365 days (33398)
2026 (30131)
2025 (32419)
2024 (37483)
2023 (42549)
2022 (53909)
2021 (58694)
2020 (57637)
2019 (51287)
2018 (39073)
2017 (36720)
2016 (37394)
2015 (44110)
2014 (39283)
2013 (35119)
2012 (35490)
2011 (35440)
2010 (33769)
Location
Africa (1210)
Alabama (117)
Alaska (7)
Arizona (475)
Arkansas (17)
Asia (50937)
Australia (8729)
California (17247)
Canada (4714)
China (2054)
Colorado (767)
Connecticut (770)
Delaware (541)
Europe (116458)
Florida (2619)
Georgia (564)
Hawaii (5)
Idaho (70)
Illinois (1481)
India (152)
Indiana (783)
Iowa (36)
Japan (775)
Kansas (158)
Kentucky (68)
Louisiana (70)
Maine (99)
Maryland (2032)
Massachusetts (12457)
Michigan (463)
Minnesota (944)
Mississippi (8)
Missouri (189)
Montana (38)
Nebraska (31)
Nevada (203)
New Hampshire (93)
New Jersey (4562)
New Mexico (38)
New York (4494)
North Carolina (2242)
North Dakota (14)
Northern California (8842)
Ohio (538)
Oklahoma (32)
Oregon (55)
Pennsylvania (3302)
Puerto Rico (38)
Rhode Island (65)
South America (1588)
South Carolina (104)
South Dakota (2)
Southern California (6890)
Tennessee (282)
Texas (2859)
United States (61082)
Utah (526)
Vermont (2)
Virginia (436)
Washington D.C. (89)
Washington State (1377)
West Virginia (4)
Wisconsin (200)
Wyoming (6)
857,066 Results for "merck sharp and dohme".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Eye disease
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
September 24, 2026
·
2 min read
·
Annalee Armstrong
cancer
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and a host of antibody-drug conjugates.
October 19, 2026
·
8 min read
·
Tristan Manalac
antibody-drug conjugate (ADC)
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Alan Northrup says gets the payload release “just right.”
October 22, 2026
·
5 min read
·
Heather McKenzie
Manufacturing
Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion
The Swiss contract development and manufacturing organization will more than double its U.S. footprint by acquiring the Merck KGaA plants.
November 3, 2026
·
2 min read
·
Nick Paul Taylor
Cancer
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first TROP2-directed ADC to do so in this setting, Merck told BioSpace.
October 26, 2026
·
4 min read
·
Heather McKenzie
Drug Development
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.
October 1, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.
September 3, 2026
·
2 min read
·
Annalee Armstrong
Cancer
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
A combination of the personalized cancer vaccine intismeran autogene and Merck’s Keytruda just barely cleared analysts’ expectations for recurrence-free survival, leaving questions as to its applicability to tumor types beyond melanoma.
October 22, 2026
·
5 min read
·
Annalee Armstrong
Vaccines
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.
October 5, 2026
·
2 min read
·
Annalee Armstrong
Manufacturing
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
Personalized cancer vaccines are getting closer to market. Merck and Moderna just showed successful manufacturing in a large Phase 3 trial, proving they can deliver the goods.
November 6, 2026
·
2 min read
·
Annalee Armstrong
1 of 85,707
Next
